Quick Facts

• Mild to moderate active Crohn's disease involving the ileum and/or ascending colon.
• Maintenance of clinical remission of mild to moderate Crohn's disease in the same affected regions (for up to three months).

---

Entocir (budesonide) is a prescribed medication intended for use in the management of specific manifestations of Crohn's disease. The primary use of this formulation is to help manage active, mild to moderate Crohn's disease where the inflammation is localized to the ileum and/or the ascending colon. This therapeutic approach aims for the induction of clinical remission to help reduce symptoms associated with active disease.

The medication is also utilized to support the maintenance of clinical remission in adult patients with mild to moderate Crohn’s disease affecting the ileum and/or ascending colon. The purpose of this maintenance use is to help prevent the return of symptoms for a period of up to three months following successful induction of remission. The therapeutic effects of this medicine are thought to be concentrated in the affected areas of the lower gastrointestinal tract.

Who can and cannot use Entocir?

Eligibility for Entocir is strictly defined by regulatory documentation across several population categories.

Contraindicated Populations

Entocir is absolutely contraindicated for patients who have a known hypersensitivity to the active ingredient, budesonide, or to any excipients in the capsule. Use is also contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) due to the risk of increased systemic exposure to the medicine.

---

Age-Specific Eligibility

Use is approved for adults for both the treatment of active Crohn's disease and for the maintenance of remission. For pediatric patients, eligibility is restricted: the medicine is approved for the treatment of active disease in those aged 8 to 17 years who weigh more than 25 kg. Use is not recommended for children younger than 8 years or those weighing 25 kg or less, as safety and efficacy have not been established in these younger groups.

---

Restricted and Conditional Use

Official labeling mandates caution in patients with specific co-existing conditions that may be sensitive to corticosteroids, including hypertension, diabetes mellitus, osteoporosis, glaucoma, and active infections (e.g., tuberculosis). Furthermore, use during pregnancy and lactation is generally not recommended, and must be avoided unless the anticipated benefit clearly outweighs the potential risks as assessed by a healthcare professional.

Interactions with other medicines and products

Entocir (budesonide) is metabolized extensively by the Cytochrome P450 3A4 (CYP3A4) enzyme, which forms the primary basis for its documented interaction profile. These are classified as pharmacokinetic interactions that modify the concentration of budesonide in the body.

---

Documented Interaction Patterns

Interaction Type	Interacting Substances	Official Outcome	Restriction
Metabolic Inhibition	Potent CYP3A4 Inhibitors (e.g., ketoconazole, HIV protease inhibitors, clarithromycin)	Significant increase in systemic exposure (AUC) of budesonide.	Avoidance noted in regulatory documents.
Food Interaction	Grapefruit Juice	Increased systemic exposure (approx. two-fold) due to inhibition of gut mucosal CYP3A4.	Avoidance of regular ingestion during treatment.
Hormonal Interaction	Oral Contraceptive Steroids (Estrogens)	Reported to raise plasma concentrations and enhance corticosteroid effects.	Use with caution noted.

---

Population-Specific Interaction Risk

Patients with severe hepatic impairment (Child-Pugh Class C) are documented to have a heightened risk of increased systemic budesonide exposure due to reduced drug elimination. Regulatory information notes that use should be avoided in this specific population. No mandatory timing separation rules are specified for co-administration with other medicinal products based on official labeling.

The pharmacological action of budesonide is defined by its anti-inflammatory mechanism, engaging its core function in a localized and precise manner, influencing gene expression and limiting systemic effects.

️ Targeted Glucocorticoid Receptor Agonism

Budesonide acts as an agonist at the intracellular Glucocorticoid Receptor (GR). This receptor binding initiates a cellular cascade by enabling the drug-receptor complex to translocate to the nucleus, where it directly modulates the transcription of genes involved in the inflammatory response.

️ Dual Modulation of Inflammatory Cascades

The key pathway effect involves the modulation of two concurrent anti-inflammatory pathways through genomic action. This mechanism both represses pro-inflammatory transcription factors like NF-kappa B (reducing cytokine synthesis) and induces anti-inflammatory proteins (blocking the PLA2 enzyme to restrict the formation of prostaglandins and leukotrienes). The physiological consequence is a reduction in pro-inflammatory cellular infiltration and vascular permeability within the tissue.

Localized Action with Systemic Constraint

The drug's mechanism is functionally tied to its targeted delivery to the ileum and ascending colon via a specialized delayed-release formulation. This promotes a high concentration gradient of the active compound in the lower bowel. Up to 90% of the absorbed budesonide is rapidly inactivated by the CYP3A4 enzyme in the liver, a process that limits the systemic bioavailability of the active compound.

How to Use Entocir

The usage of Entocir (budesonide) is precisely defined by its design as a delayed-release capsule intended for oral administration. This method ensures the medicine is delivered locally to the inflamed areas of the lower small intestine (ileum) and the beginning of the large intestine (ascending colon). The capsule must be swallowed whole with water and must not be crushed, chewed, or broken, as this would compromise the special enteric coating necessary for targeted release.

---

Standard Dosing and Frequency

Entocir is taken once daily, typically in the morning, which establishes a consistent 24-hour dosing schedule. The dosage and duration depend on the phase of treatment:

Indication Phase	Standard Adult Dose	Duration Limit
Induction of Remission	9 mg once daily	Up to 8 weeks
Maintenance of Remission	6 mg once daily	Up to 3 months

---

Administration Requirements and Tapering

The medicine may be taken with or without food. A key procedural instruction is the need to avoid consuming grapefruit or grapefruit juice, as this can interfere with the proper utilization of the drug. For patients who cannot swallow the capsule whole, the entire capsule contents may be opened and mixed with a tablespoon of soft, cool applesauce and consumed immediately, followed by eight ounces of water.

Discontinuation of Entocir requires a gradual tapering process. Upon completion of the full course or prior to stopping, the dosage must be slowly reduced (e.g., from 6 mg to 3 mg daily) over a period of two to four weeks, rather than stopping abruptly. Specific dose adjustments are recommended for pediatric patients and those with moderate hepatic impairment, where a reduction to 3 mg daily should be considered.

Entocir (Budesonide Delayed-Release Capsules): Clinical Evidence

Entocir (budesonide) is an orally administered corticosteroid formulated for delayed release, designed to primarily deliver the medication to the ileum and ascending colon. This targeted delivery is intended to maximize local anti-inflammatory action while limiting systemic exposure due to high first-pass metabolism in the liver.

Findings in Crohn's Disease

Clinical trials focusing on the induction of remission in adults with mild to moderate active Crohn's disease, typically involving the ileum and/or ascending colon, have provided key insights.

• Induction of Remission: Studies have observed that budesonide 9 mg/day was more effective than placebo for inducing clinical remission (defined by a Crohn's Disease Activity Index [CDAI] score below 150) at 8 to 10 weeks. The rate of remission with this formulation was generally lower compared to conventional systemic steroids like prednisolone, but the formulation was associated with a lower incidence of common steroid-related side effects.
• Maintenance of Remission: Evidence regarding the long-term effectiveness of budesonide for maintaining remission in Crohn's disease has been mixed, with some analyses suggesting it may delay relapse but may not be effective for maintaining remission over a 12-month period.

Adrenal Function and Safety

Compared to systemic corticosteroids, budesonide delayed-release capsules have generally been associated with a lower risk of adrenal suppression. However, the use of this formulation, especially for extended periods, has shown an increased risk of an abnormal ACTH test compared with placebo in some studies, indicating a potential impact on the adrenal axis. Common adverse events reported in trials include headache, nausea, and symptoms related to the presence of Cushingoid features.

Condition	Indication Focus	Key Efficacy Finding (vs. Placebo)
Crohn's Disease (CD)	Induction of Remission	Observed to be more effective.
Crohn's Disease (CD)	Maintenance of Remission	Evidence is controversial; may not sustain remission long-term.

Common questions about Entocir (FAQ)

Q: How quickly does Entocir start to work for inflammation?

A: Studies and official information indicate that the medicine's main effect is measured over several weeks. Clinical studies examining the induction of remission often measure primary effects between 8 and 10 weeks of treatment. However, some evidence in pediatric patients suggests an initial clinical response may be observed within the first two weeks of use.

Q: Will I have withdrawal symptoms when I stop taking Entocir?

A: Regulatory documents state that discontinuation must be done using a gradual reduction in dosage (tapering). Abruptly stopping the medicine may lead to symptoms related to steroid withdrawal or acute adrenal axis suppression, which is when the body's adrenal glands do not produce enough hormones. Concerns regarding discontinuation should be discussed with a healthcare provider.

Q: Can Entocir cause mood changes or make me feel anxious?

A: Official safety information lists mood changes, nervousness, and anxiety among the possible psychiatric adverse effects reported with the use of this class of medicine. Changes in mood are listed as possible effects and are generally reported to a healthcare provider.

Q: Does Entocir make me gain weight?

A: The official safety profile notes that weight gain is a reported side effect of the medicine. You may also notice other manifestations of systemic corticosteroid exposure, such as a rounding of the face (sometimes called moon face).

Q: Is it possible for Entocir to cause bone thinning (osteoporosis)?

A: Yes, official safety information indicates that the long-term use of corticosteroids is associated with the risk of developing weak bones (osteoporosis) or reductions in bone mineral density. Caution is also advised for patients who already have existing osteoporosis.

Q: Does Entocir affect my blood sugar levels?

A: As a type of corticosteroid, the medicine may cause elevated blood sugar levels, a condition known as hyperglycemia. Official documentation advises that patients with existing diabetes may require close monitoring of their blood sugar during treatment.

Q: Does Entocir affect my immune system?

A: Corticosteroid medicines like Entocir are associated with a decreased ability of the body to fight infections (immunosuppression). This means that there is an increased risk of infection, as noted in official warnings.

Q: What is the official research evidence for using Entocir in children?

A: Official approval for its use in children aged 8 years and older, who weigh over 25 kg, was based on clinical studies. The effectiveness in these studies was assessed using tools like the Pediatric Crohn's Disease Activity Index (PCDAI), with results supporting its use to help induce remission.

Q: Can Entocir cure my condition, or does it just manage symptoms?

A: The medicine is not classified as a cure for chronic inflammatory bowel conditions. Official indications describe the medicine's role for the treatment and maintenance of clinical remission, focusing on managing inflammation and symptoms associated with the disease.

Q: Why do some people need to take Entocir for a specific time period?

A: The use of the medicine is limited to a defined duration for both the active treatment phase and the maintenance phase. This is because continued use beyond three months has not been shown to provide substantial additional clinical benefit, according to regulatory documentation.

Q: Is Entocir a long-term medicine, or only for flare-ups?

A: The medicine is primarily intended for the treatment of active disease (flare-ups) and for the short-term maintenance of clinical remission (up to 3 months in adults). After this period, official recommendations state that the medicine should be discontinued via a gradual tapering process.

Q: If Entocir is targeted, does that mean it has fewer side effects?

A: The targeted delivery is intended to limit the amount of medicine that affects the rest of the body. Clinical evidence comparing this medicine to conventional oral corticosteroids suggests it is associated with a lower incidence of common systemic steroid-related side effects, such as developing Cushingoid features.

Q: Is it normal to feel dizzy or lightheaded after starting Entocir?

A: The official safety profile lists dizziness as a common adverse reaction, meaning it occurred in 5% or more of patients in clinical trials. Severe or persistent symptoms are typically discussed with a healthcare provider.

Q: What happens if I forget to take an Entocir capsule?

A: Regulatory information advises that if a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. Official guidance indicates that the dosage should not be doubled to make up for a missed dose.

Q: Is Entocir safe for people over the age of 65?

A: The official information advises that patients aged 65 years and older should use the medicine with care. This is because older patients may have a higher risk of experiencing side effects when taking corticosteroids.

Q: Does Entocir work for conditions other than inflammatory bowel disease?

A: The active ingredient, budesonide, is used in other specific formulations to treat conditions like ulcerative colitis and primary immunoglobulin A nephropathy. However, the Entocir EC delayed-release capsule formulation is specifically indicated for Crohn's disease.

Q: Why do official documents mention 'active Crohn's disease' when talking about Entocir?

A: Official labeling specifies the use for 'active' Crohn's disease to precisely define the indication for the medicine. This is key to the drug's role as an induction therapy, which means it is used to bring the disease under control, distinguishing it from the phase of sustained remission.

Q: Why do some patients report feeling better immediately while others take weeks?

A: Clinical trial data indicates that the time required for the medicine to reach its peak concentration in the bloodstream is highly variable among individual patients. This variability may be one factor contributing to differences in the time until patients report feeling an effect.

Q: Are there generic versions of Entocir available, and are they the same?

A: Yes, regulatory authorities have approved generic versions of the delayed-release budesonide capsule. The FDA classifies these generic products as bioequivalent to the brand-name medicine, meaning they are expected to work in the same way.

Q: Does Entocir impact fertility in men or women?

A: The official prescribing information contains a section on Impairment of Fertility that outlines findings from animal studies (rats). No explicit human data on the impact on fertility is detailed in the regulatory label.

Q: How does the medicine know to target the bowel?

A: The medicine's targeted action is achieved by a special delayed-release coating on the capsule's tiny granules. This coating is designed to prevent the drug from dissolving in the stomach, ensuring it releases the medicine only when it reaches the specific pH (acidity level) of the lower digestive tract, primarily the ileum and ascending colon.

Q: Is Entocir used for microscopic colitis?

A: The active ingredient, budesonide, has been examined and used in clinical studies related to microscopic colitis. However, the Entocir EC delayed-release capsule formulation is specifically indicated for Crohn's disease, as noted in the official regulatory documents.

Q: Can Entocir impact my ability to fall asleep?

A: The official safety profile lists insomnia (trouble sleeping) and sleep disorder as reported psychiatric adverse effects. Difficulty sleeping is reported as a potential side effect of the medicine.

Q: How is the safety of Entocir monitored after it is approved?

A: Regulatory approval includes requirements for the manufacturer to continuously update the safety profile of the drug. This involves submitting new safety information and reporting all observed adverse events to the governing bodies to ensure ongoing monitoring of the medicine's risk profile.

Official Storage Requirements

Storage of Entocir (budesonide) capsules must strictly adhere to the conditions detailed in the regulatory labeling to maintain the product's integrity. The medicine must be stored at a temperature that does not exceed 30°C (86°F).

To ensure stability and protect the contents from degradation, the capsules must be stored in the original container and the cap must be firmly replaced after each use. This is mandatory for protecting the medicine from light and moisture.

Storage Constraint	Requirement
Temperature Limit	Do not store above 30°C (86°F).
Protection	Store in the original container to protect from light and moisture.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

When disposing of unused or expired Entocir, patients must follow local requirements for pharmaceutical waste. Regulatory bodies explicitly state that the medicine must not be thrown away via wastewater or household waste to help protect the environment.